Skip to main content
Top

23-10-2023 | Thyroid Cancer | Editor's Choice | News

Phase 3 data support first-line use of selpercatinib for RET-mutant medullary thyroid cancer

Author: Dr. Shreeya Nanda

medwireNews: The phase 3 LIBRETTO-531 trial has demonstrated the superiority of selpercatinib, a highly selective RET kinase inhibitor, over approved multikinase inhibitors in people with advanced RET-mutant medullary thyroid cancer.

Related topics

Test your knowledge with Case-Based Clinical Insights

Oncology and Hematology Cases

45/♀ with increasing weakness, loss of appetite, diarrhoea and oedema – Case 29

A 45-year-old female patient complains that she has been getting weaker and weaker for several months. She has no appetite and suffers from diarrhoea. Immunofixation shows monoclonal lambda light chains in the serum. What is your tentative diagnosis?

48/♀ with increasing spontaneous haematomas all over her body – Case 37

A 48-year-old female patient feels listless and reports petechiae occurred for the first time. In the last 3 days, she had reportedly developed severe toothache and fever. The blood count shows severe pancytopenia. What are your first steps?

49/♀ with lymphoedema of the arm in condition of metastasised triple-negative breast carcinoma – Case 43

The 49-year-old female patient presents with significant swelling of the right arm. She reports having been diagnosed with breast cancer 1½ years ago, followed by surgical removal of the tumour. She had then received chemotherapy and irradiation. How do you proceed?

53/♂ with movement-dependent pain in the left anterior pelvis and bloody urine – Case 39

A 53-year-old man complains of increasing pain in the left anterior pelvis, which is described as movement-dependent with radiation into the left lower extremity. For several months, he had noticed bloody urine from time to time without pain during micturition. What are your suspicions?